Provides customized back-office compliance software for financial services firms. Offers multi-pay commission processing systems. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.5× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 6 years, sales grew about 19% a year on average.
Sales run at $3.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 41 buys and 25 sells. Management buying with its own money is usually read as a good sign.
A loss of $3.6M against $3.0M in annual sales.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.